Home
RNA Therapeutics
21 February - 22 February 2018
RNA Therapeutics

SAE Media Group announces the 9th Annual RNA Therapeutics Conference in London on February 21st - 22nd 2018. As the requirement for targeted solutions for chronic diseases continues to grow, the interest of pharmaceutical and biotech companies has increasingly focused towards RNA therapeutics, such that by 2020, the RNA Therapeutics Market is predicted to attain $1.2 billion.http://bit.ly/2xtvCH1

One of the main challenges in RNA Therapeutics continues to be bridging the gap between in-vivo and in-vitro models, hear key case studies on the development on the latest delivery systems and evaluate with key industry leaders the lessons they’ve learnt whilst developing an RNA therapeutic.

Join us this February 2018, as SAE Media Group’s RNA Therapeutics Conference brings together industry experts from leading RNA therapeutics companies to analyze and evaluate the latest advancements including SaRNA as a potential therapeutic for people with liver cancer, advances in targeted delivery of nucleotides beyond the liver and the latest developments in delivery systems, such as exosomes and nanocomplexes.
 

FEATURED SPEAKERS

James Hamilton

James Hamilton

Vice President Clinical Development, Arrowhead Pharmaceuticals, Inc.
Janne Turunen

Janne Turunen

Director Technologies, ProQR Therapeutics
Kai Wilkens

Kai Wilkens

Senior Director Europe, Advanced Cell Diagnostics SRL
Nagy Habib

Nagy Habib

Chairman and Co-Founder, MiNA Therapeutics
Natalie Pursell

Natalie Pursell

Senior Scientist II, Dicerna Pharmaceuticals, Inc.
Shalini  Andersson

Shalini Andersson

Senior Director Drug Metabolism & Pharmacokinetics, AstraZeneca R&D

Achim Schneeberger

CMO, Accanis
Achim Schneeberger

Achim Schneeberger

CSO, Accanis
Achim Schneeberger

Birgit Pless

Deputy Head of Project Management, BioNTech AG
Birgit  Pless

Dr. Birgit Pless received her Diploma with honours from the Department of Microbiology and Molecular Biology at the Free University of Berlin in 2006. She received her Ph.D. in Pharmaceutical Biology from Goethe University in 2011 and was a recipient of a scholarship from the Frankfurt International Research School for Translational Biomedicine ‚ FIRST‘ for her PhD studies.
Since 2011, she is working in the project management department of BioNTech, where she has been involved in the first clinical trials of BioNTech, bringing BioNTech’s innovative vaccines into the clinic. She is currently Deputy Head of Project Management.
 

Christian Reinsch

Principal Investigator & Co-Founder, Lipocalyx
Christian Reinsch

David Simmons

Head of Biology, Storm Therapeutics
David Simmons

Ekkehard Leberer

Senior Director , Sanofi
Ekkehard Leberer

Dr. Leberer received his Ph.D. in Biology at the University of Konstanz, Germany (1986). He conducted post-doctoral training in molecular biology at the Banting and Best Institute of the University of Toronto, Canada, and then became a Professor of Biochemistry at the University of Konstanz, Germany (1992). He is currently responsible for R&D Alliance Management at Sanofi, and is the Scientific Managing Director of the Innovative Medicine Initiative COMPACT Consortium on the delivery of biopharmaceuticals across biological barriers and cellular membranes (www.compact-research.org).
Since joining Hoechst Marion Roussel in 1998, Dr. Leberer carried out various managing roles in this company, Sanofi’s predecessor companies and Sanofi itself, including responsibilities in functional genomics, biological sciences and external innovation for oligonucleotide-based therapeutics. He has also served as Head of Biotechnology Germany and a member of the Scientific Review Committee of Aventis Pharma Germany.
Prior to joining pharmaceutical industry, Dr. Leberer served as Senior Research Officer in genetics and genomics at the Biotechnology Research Institute, National Research Council of Canada, Montreal. His research has focused on the molecular mechanisms of signal transduction and the role of signalling molecules in human diseases. He is the principal discoverer of the p21 activated protein kinase (PAK) family of cell signalling proteins and of novel virulence-inducing genes in pathogenic fungi. He is co-author of more than 60 publications in prestigious peer-reviewed journals including Nature and Science.
 

Elena Bichenkova

Reader in Medicinal Chemistry, Manchester University
Elena Bichenkova

Having graduated in Chemistry (BSc - 1981; MSc - 1983) with a PhD in NMR structural biology (1993, Russia), Elena continued her research in the USA at Purdue University (1992, 1994) and then at the University of Texas (1996) collaborating with the first-rank NMR laboratory of Prof. David Gorenstein. After being awarded a Royal Society/NATO Postdoctoral Fellowship in 1996, she joined the University of Manchester as a Research Fellow. In January 2004 Elena was appointed by Manchester Pharmacy School as a Lecturer in Medicinal Chemistry followed by promotion to Senior Lecturer (2009) and then to Reader (2013).
 

Giulietta Maruggi

Lab Head, Vector Biology, GSK
Giulietta Maruggi

Helen McCarthy

Chair of Nanomedicine, Queen’s University Belfast’s, School of Pharmacy
Helen  McCarthy

Professor McCarthy is the Chair of Nanomedicine at Queen’s University Belfast’s School of Pharmacy. As such McCarthy comes from an environment where 11 products have been commercialized. At Queen’s University Belfast, Helen leads a lab of 3 post-doctoral researchers and 6 PhD students where she has been specializing in peptide based drug delivery systems. To that point, she is the inventor of the RALA peptide and further innovations that allow for full bio-distribution and cancer targeting using a peptide based drug delivery system. Over the past 11 years, her work with the RALA peptide has been the refinement of the nanoparticle system and generation of numerous in vivo proof-of-concept studies showing potential in nucleic acid delivery as well as a more recent demonstrations with anionic small molecules such as nucleotides and bisphosphonates.

James Ogle

European Patent Attorney and UK Chartered Patent Attorney, Hoffmann Eitle
James  Ogle

James Ogle, PhD, is a European and UK patent attorney, and partner at pan-European law firm Hoffmann Eitle. Dr. Ogle acts for clients across the life sciences, with broad experience in RNA-based technologies. Much of his work focuses on oppositions and appeals at the European Patent Office, and also includes advice on new inventions, drafting/prosecuting patent applications, patent-related due diligence, SPCs, and aspects of pan-European litigation. Dr. Ogle graduated from Regensburg University (Germany) in 2000 and obtained his PhD at Cambridge University (UK) with Venki Ramakrishnan in 2004, on research on mRNA translation closely connected with Ramakrishnan’s 2009 Nobel Prize.

James Hamilton

Vice President Clinical Development, Arrowhead Pharmaceuticals, Inc.
James Hamilton

Dr. James Hamilton currently serves as Vice President Clinical Development at Arrowhead Pharmaceuticals where he is responsible for all aspects of clinical trial design, implementation and execution. In this role, Dr. Hamilton managed the ARC-520 and ARC-AAT global programs through Phase 2 of development. Previously, Dr. Hamilton was Medical Director and Head of Corporate Development at Arrowhead. He led Arrowhead’s acquisition of the Novartis RNAi assets and led Arrowhead’s $670 Million cardiovascular deal with Amgen. Dr. Hamilton previously served as CEO of Calando Pharmaceuticals. He earned an MD and MBA at The Ohio State University and is board certified in Emergency Medicine.

Janne Turunen

Director Technologies, ProQR Therapeutics
Janne Turunen

Janne Turunen, PhD, is Director Technologies at ProQR Therapeutics, and serves as the scientific lead for the team developing the Axiomer® RNA editing technology. Prior to joining ProQR in 2015, Dr. Turunen did research on multiple aspects of RNA biology in academia, both in basic science and in translational applications: He received his PhD degree from the University of Helsinki in 2012 on his research on the mechanisms regulating pre-mRNA splicing, followed by postdoctoral studies on oligonucleotide therapeutics for immunological disorders at the Karolinska Institute in Stockholm.

Kai Wilkens

Senior Director Europe, Advanced Cell Diagnostics SRL
Kai Wilkens

Dr. Kai Wilkens completed his Biology studies and PhD thesis in Molecular Biology in Bochum working in the field of Gene Expression Control. He did clinical research for a couple of years and after that held different positions in several Life Science companies pioneering innovative technologies and mainly enabling new approaches in translational and clinical research. These included MWG Biotech, Panomics/Affymetrix, Mesoscale Discovery and now Advanced Cell Diagnostics.

Kirsty Wydenbach

Senior Medical Assessor, Deputy Unit Manager, Clinical Trials Unit, Medicines and Healthcare products Regulatory Agency
Kirsty Wydenbach

Kirsty joined the MHRA in 2009 as a Medical Assessor in the Clinical Trials Unit. She has been specifically involved in the UK regulation of clinical trials across all therapy areas and all phases of development, including trials for both chemical and biological products, Advanced Therapy Products and many first-in-man studies. She has also been involved in European discussions aiming to establish an EU harmonised approach to decisions regarding clinical trials, particularly for Developmental Safety Update Reports (DSURs) and also including Voluntary Harmonised Procedure (VHP) applications. More recent EU priorities have included the new Clinical Trial Regulation and Kirsty currently sits on the safety subgroup of the Clinical Trials Facilitation Group (CTFG) that is working on how this will be implemented. She is also the co-chair for safety for the EU NTC Curriculum for European regulatory agency assessors and was an EMA expert for the update of the First-in-Human guideline.

Nagy Habib

Chairman and Co-Founder, MiNA Therapeutics
Nagy Habib

Professor Nagy Habib is Head of HPB Surgery at the Hammersmith Campus of Imperial College London and also a serial founder and entrepreneur of life sciences ventures. He is co-founder of several biotech companies: EMcision Ltd, OmniCyte Ltd, MiNA Therapeutics Ltd, Apterna Ltd, Medeva Plc and Bioenvision Ltd. Previously he was Pro-Rector for Commercial Affairs at Imperial College London.
He is a translational researcher who pioneered the first clinical trial of the use of plasmid and adenovirus for the treatment of liver cancer, as well as the use of plasmid gene therapy in hydrodynamic gene delivery. He was the Principal Investigator of world first clinical trials published on the use of adult bone marrow-derived stem cells for the treatment of patients with liver insufficiency and CD34+ cells for patients with stroke.
He was the inventor and co-author on the first publication to describe the use of radiofrequency energy in devices for liver surgery (Habib 4X), and interventional endoscopy (Habib™ EndoHPB and Habib™ EUS-RFA).
Professor Habib holds a gold award from the Advisory Committee for Clinical Excellence which is given to recognise and reward the exceptional contribution of NHS consultants, over and above that normally expected in a job, to the values and goals of the NHS and to patient care, and he was named as one of Britain’s top surgeons in December 2011 by the Saturday Times Magazine.
In the 2014 Research Excellence Frame work (REF) exercise, which is the system for assessing the quality of research in UK in higher education institutions, Professor Habib was rated as a 4* researcher which is the highest ranking. His work on radiofrequency ablation was selected among those that have had the most “Impact on Society” and was ranked 1 with a score of 93%. In January 2015 he was elected as a Foreign Member by the prestigious French Académie Nationale de Chirurgie.

 

Natalie Pursell

Senior Scientist II, Dicerna Pharmaceuticals, Inc.
Natalie Pursell

Natalie Pursell joined the Translational Biology Group at Dicerna in 2014. She is responsible for the preclinical development of GalXC RNAi therapeutics for multiple rare disease programs. Her work elucidating the mechanism of action for Dicerna’s GalXC RNAi therapeutic targeting LDHA was instrumental in the recent initiation of Phase 1 clinical trials for DCR-PHXC. Prior to joining Dicerna, Natalie spent 2 years at Curis Inc. conducting preclinical research on multi-targeted small molecule inhibitors for several oncology programs.
Natalie holds a Ph.D. in Biochemistry from the University of Massachusetts Medical School and B.A. degrees in Chemistry and Biology from Colby College.
 

Nigel Horscroft

Area Head of Molecular Therapy , CureVac GmbH
Nigel Horscroft

Oliver Rausch

VP Research & Development , Storm Therapeutics
Oliver Rausch

Oliver Rausch is Vice President Research and Development at Storm Therapeutics. He has overall responsibility for Storm’s biology platform and drug discovery pipeline, and worked closely with Storm’s scientific founders to secure the initial £12M series A investment that launched Storm in 2016.

Prior to Storm, Oliver was Programme Director at the National Institute for Health Research (NIHR) where he led industry-focussed collaboration initiatives in experimental medicine and early phase clinical trials. He has twenty years of drug discovery experience in Inflammation, Neurology and Oncology gained at Cellzome, UCB and GSK. He holds a degree in Biochemistry from the Free University Berlin and a PhD in Biochemistry and Cell Biology from the Institute of Cancer Research in London.
 

Paul Agris

Founding Director, The RNA Institute, SUNY University at Albany
Paul Agris

Paul Agris founded The RNA Institute, a global alliance of top RNA biomedical researchers creating tools for RNA applications. Formerly, Agris was Head of NCSU’s Department of Biochemistry and founded and led the RNA Society of North Carolina for more than a decade. He was an Assistant, Associate and full Professor in the Division of Biological Sciences and Department of Medicine at the University of Missouri-Columbia. Agris received his graduate degree from MIT, and was a postdoctoral fellow at Yale.Paul Agris founded The RNA Institute, a global alliance of top RNA biomedical researchers creating tools for RNA applications. Formerly, Agris was Head of NCSU’s Department of Biochemistry and founded and led the RNA Society of North Carolina for more than a decade. He was an Assistant, Associate and full Professor in the Division of Biological Sciences and Department of Medicine at the University of Missouri-Columbia. Agris received his graduate degree from MIT, and was a postdoctoral fellow at Yale. For over 50 years, he has conducted funded RNA science leading to publications, patents and the founding of two companies.

Shalini Andersson

Senior Director Drug Metabolism & Pharmacokinetics, AstraZeneca R&D
Shalini  Andersson

Shalini is Senior Director and Head of Drug Metabolism & Pharmacokinetics within the Cardiovascular and Metabolic Disease Innovative Medicines unit (CVMD IMED) since December 2010. She is also a member of the Management Team for CVMD IMED as well as of the Review Board for CVMD drug projects. Currently Shalini is also leading Targeted Drug Delivery within CVMD therapy area including the open innovation collaboration with IONIS Pharmaceuticals. She is also the project leader for subcutaneous delivery of modified RNA to man.
Shalini received her PhD in 1989 at the University of Linköping, Sweden and was a research fellow at the Institute of Pharmaceutical Chemistry, University of Münster, Germany. She joined AstraZeneca in 1997.She is the author or co-author of over 34 peer reviewed articles, 2 book chapters and 4 patents.

 

Steffen Panzner

Managing Director, Lipocalyx
Steffen Panzner

Dr. Panzner is an expert in oligonucleotide delivery; author of more than 35 patent families and numerous scientific publications covering novel concepts for oligonucleotide delivery such as the Viromer® (virus-mimicking polymer) and the Smarticles® (amphoteric liposome) technology. Products based on these technologies are in phase 2 clinical trials or earlier stages of development.
Dr. Panzner was Founder and CSO of Novosom AG between 1999 and 2010 and is Founder and CEO of Lipocalyx GmbH which started 2011. He also is a consultant and CMC expert for pharma and biotech companies as well as for VC firms.
 

Stephen Hart

Professor in Molecular Genetics, University College London
Stephen Hart

Stephen Hart is a Professor in Molecular Genetics at UCL Great Ormond Street Institute of Child Health. He obtained his PhD from the University of Cape Town and has worked in the field of genetic therapies for more than 20 years with more than 100 publications. His current research activities include the development of synthetic nanoparticles for the delivery of nucleic acid therapeutics including siRNA and mRNA for the treatment of paediatric diseases including cystic fibrosis, primary ciliary dyskinesias and neuroblastoma. He is the founder of Nanogenic Solutions Ltd, a UCL spin-out company commercialising siRNA and gene delivery formulations.

sponsors

Conference agenda

clock

8:30

Registration & Coffee

clock

9:00

Chairman's Opening Remarks

Nagy Habib, Chairman and Co-Founder, MiNA Therapeutics

clock

9:10

Developing mRNA therapeutics for Skin Diseases

Achim Schneeberger

Achim Schneeberger, CMO, Accanis

• Skin offers various opportunities with regard to development of mRNA-based therapeutics: diseases with validated molecular targets/attractive markets and direct access facilitating quantification of mRNA expression/clinical activity
• mRNA is a new drug format capable of exceeding existing protein-based therapeutics.
• Developing proprietary IVT-mRNAs addressing validated targets for specific skin conditions
• Systematically modifying specific IVT-mRNAs and testing the most interesting ones in skin explant systems varying formulation and delivery.
 

clock

9:50

Utilising Small Activating RNA (saRNA) for Therapeutic Opportunities

Nagy Habib, Chairman and Co-Founder, MiNA Therapeutics

• Harnessing the innate mechanism of gene activation
• Evaluating how saRNA can be used to restore the expression of CCAAT/enhancer binding protein alpha (C/EBP-a)
• Achieving proof of concept: Clinical applications and therapeutic opportunities this offers
• Lessons learnt during Phase I Clinical Study of MTL-CEBPA in Patients with Liver Cancer

clock

10:30

Morning Coffee

clock

11:00

Therapeutic RNA editing by Axiomer® editing oligonucleotides

Janne Turunen, Director Technologies, ProQR Therapeutics

• Therapeutic opportunity for treating genetic disorders arising from G-to-A point mutations
• Basis of the Axiomer® approach: site-specific adenosine-to-inosine (A-to-I) base editing to restore the correct sequence with editing oligonucleotides (EONs) as the only active component
• The novel design of the EONs to achieve recruitment of the endogenous ADAR editing enzymes

clock

11:40

MicroRNA Therapeutics: Opportunities and Challenges for Targeting the Pathways of Human Disease

Ekkehard Leberer, Senior Director , Sanofi

• MicroRNAs regulate by the mechanism of RNA interference (RNAi) biochemical pathways involved in human diseases
• MicroRNA-21 has been implicated in multiple organs with fibrosis and cancer
• The presentation will summarize opportunities and challenges of developing microRNA based oligonucleotide therapeutics and illustrate the generation of an anti-fibrotic oligonucleotide drug targeting microRNA-21
 

clock

12:20

miRNases: Novel peptide-oligonucleotide bioconjugates that silence miR-21 in lymphosarcoma cells

Elena Bichenkova, Reader in Medicinal Chemistry, Manchester University

• The key challenges in the traditional DDD process of small molecule drugs
• Some emerging  opportunities in attempt to overcome the key issues
• New avenues for development of novel therapeutic interventions against cancer
• Development of ‘intelligent’ anti-cancer therapeutics against oncogenic microRNAs

clock

13:00

Networking Lunch

clock

14:00

RNAscope - Specific single-copy detection of any RNA in tissue

Kai Wilkens, Senior Director Europe, Advanced Cell Diagnostics SRL

• RNAscope - Specific single-copy detection of any RNA in tissue
• Tracking of therapeutic RNA delivery without surrogates
• Pharmacodynamics for RNA and Cell therapies
• Easy target validation and biomarker development
 

clock

14:40

Self-amplifying mRNA vaccines

Giulietta Maruggi

Giulietta Maruggi, Lab Head, Vector Biology, GSK

• Broad utility against infectious diseases
• Facilitation of a rapid response to emerging infectious diseases
• Mechanism of action
 

clock

15:20

Using mRNA technology in the development of novel cancer vaccines

Birgit Pless, Deputy Head of Project Management, BioNTech AG

  • BioNTech’s pharmacologically optimized mRNA technology provides an easy and effective way to trigger T-cell immune responses in vivo.
  • Introduction of BioNTech’s immunotherapy platforms (shared, personalized and individualized approaches)
  • Development of a nanoparticle formulation for systemic RNA delivery
  • clock

    16:00

    Afternoon Tea

    clock

    16:30

    Harnessing the power of RNA Epigenetics – targeting RNA modifying enzymes for the treatment of cancer

    David Simmons

    David Simmons, Head of Biology, Storm Therapeutics

    • Over 150 different chemical modifications have been identified on RNA molecules.
    • The role of these modifications in the maturation and regulation of coding and non-coding RNA is becoming increasingly prominent.
    • Utilising the research of world-leading founders Professors Kouzarides and Miska in the field of RNA epigenetics to pioneer the development of small molecule inhibitors of previously untargeted RNA-modifying enzymes (RMEs) to interfere with key RNA pathways and mechanisms
     

    clock

    17:10

    RNAoptimizer – From mRNA to product

    Nigel Horscroft

    Nigel Horscroft, Area Head of Molecular Therapy , CureVac GmbH

    • CureVac’s RNAoptimizer provides optimal mRNA for each target indication
    • The RNAoptimizer includes sequence optimization, formulation & delivery adjustment and protein design improvement
    • RNAoptimizer is developed as robotic assisted process
     

    clock

    17:50

    Chairman’s Closing Remarks and Close of Day One

    Nagy Habib, Chairman and Co-Founder, MiNA Therapeutics

    clock

    8:30

    Registration & Coffee

    clock

    9:00

    Chairman's Opening Remarks

    Nagy Habib, Chairman and Co-Founder, MiNA Therapeutics

    clock

    9:10

    Gaining Regulatory Approval and Mitigating Risks during Clinical Trials

    Kirsty Wydenbach, Senior Medical Assessor, Deputy Unit Manager, Clinical Trials Unit, Medicines and Healthcare products Regulatory Agency

    • Expectations of a regulator and how to report your results 
    • Overcoming common governing pitfalls
    • Updates of new and upcoming regulations and how you may be affected

    clock

    9:50

    Patenting RNA Therapeutics

    James Ogle, European Patent Attorney and UK Chartered Patent Attorney, Hoffmann Eitle

    • Drafting a successful new patent application
    • Advice regarding oppositions and appeals before the European Patent Office
    • Avoiding risks associated with patents, including patent infringement and patent transactions
    • Moving beyond compound protection, which types of follow-up protection should be considered by innovators
     

    clock

    10:30

    Morning Coffee

    clock

    11:00

    Local and Systemic Oligonucleotide Delivery Using RALA Peptide Nanoparticles

    Helen McCarthy, Chair of Nanomedicine, Queen’s University Belfast’s, School of Pharmacy

    •  High Transfection Efficiency with Low Associated Toxicity
    •  Tunable Systemic In Vivo Biodistribution
    •  Ability to Concentrate into Tumours/Cancer Cells
    •  Simple, Easy to Use Formulation and Scale Up
     

    clock

    11:40

    Advances in Targeted Delivery of Nucleotides Beyond the Liver

    Shalini Andersson, Senior Director Drug Metabolism & Pharmacokinetics, AstraZeneca R&D

    • Potential targeting approaches for delivery to tissues and cell types beyond the liver, including the cardiovascular, metabolic and renal systems
    • Overcoming challenges, including insufficient pharmacokinetic properties and poor cellular uptake
    • Evaluation of the drugs in the pipeline for AstraZeneca

    clock

    12:20

    Networking Lunch

    clock

    13:20

    Viromer preclinical validation

    Christian Reinsch

    Christian Reinsch , Principal Investigator & Co-Founder, Lipocalyx

    • The Viromer technology
    • Optimization both for Chemistry and Formulation
    • Application in Preclinical Models
     

    clock

    14:00

    Utilising an alternative siRNA delivery approaches to target liver hepatocytes

    Natalie Pursell, Senior Scientist II, Dicerna Pharmaceuticals, Inc.

    • Advantages of using GalXC RNAi platform delivery approach over a traditional Lipid Nanoparticle (LNP) Delivery System
    • Chemistry and challenges of this platform
    • Advantages of using Dicer Substrate short-interfering RNAs (DsiRNAs), for targeted therapies
    • Case study: Dicerna’s drug pipeline and pre-clinical trials, which utilize the alternative delivery approach to treat disease
     

    clock

    14:40

    Afternoon Tea

    clock

    15:10

    The Evolution of RNAi Delivery at Arrowhead

    James Hamilton , Vice President Clinical Development, Arrowhead Pharmaceuticals, Inc.

    • Older RNAi delivery technologies
    • Dynamic Polyconjugates: Pre-clinical and Clinical Experience
    • Arrowhead Single Molecule RNAi Conjugates
     

    clock

    15:50

    Delivery of a MYCN siRNA Therapy to Neuroblastoma by a Targeted Nanocomplex

    Stephen Hart, Professor in Molecular Genetics, University College London

    • Neuroblastoma is a tumour of nerves with primary tumours usually located in the abdomen.
    • Neuroblastoma is the most common solid tumour in childhood with worst prognosis cases involving amplification of the MYCN proto-oncogene.
    • Silencing of MYCN induces differentiation, apoptosis leading to tumour eradication or slow growth.
    • Integrin-targeted, lipid-peptide nanocomplexes enable systemic delivery to neuroblastoma tumours specifically, avoiding uptake by liver and other organs.
     

    clock

    16:30

    Chairman’s Closing Remarks and Close of Day Two


    CMO
    Accanis
    CSO
    Accanis
    Deputy Head of Project Management
    BioNTech AG
    Principal Investigator & Co-Founder
    Lipocalyx
    Head of Biology
    Storm Therapeutics
    Senior Director
    Sanofi
    Reader in Medicinal Chemistry
    Manchester University
    Lab Head, Vector Biology
    GSK
    Chair of Nanomedicine
    Queen’s University Belfast’s, School of Pharmacy
    European Patent Attorney and UK Chartered Patent Attorney
    Hoffmann Eitle
    Vice President Clinical Development
    Arrowhead Pharmaceuticals, Inc.
    Director Technologies
    ProQR Therapeutics
    Senior Director Europe
    Advanced Cell Diagnostics SRL
    Senior Medical Assessor, Deputy Unit Manager, Clinical Trials Unit
    Medicines and Healthcare products Regulatory Agency
    Chairman and Co-Founder
    MiNA Therapeutics
    Senior Scientist II
    Dicerna Pharmaceuticals, Inc.
    Area Head of Molecular Therapy
    CureVac GmbH
    VP Research & Development
    Storm Therapeutics
    Founding Director
    The RNA Institute, SUNY University at Albany
    Senior Director Drug Metabolism & Pharmacokinetics
    AstraZeneca R&D
    Managing Director
    Lipocalyx
    Professor in Molecular Genetics
    University College London

    Sponsors and Exhibitors

    Supporters

    [ATTENDEE LIST 2018] - THIS YEAR'S LIST OF ATTENDEES

    Download

    [SPEAKER INTERVIEW] - Nagy Habib, Head of HPB Surgery, Imperial College London

    Download

    [SPEAKER INTERVIEW] - Ekkehard Leberer, PhD, Professor of Biochemistry, Senior Director, R&D Alliance Management

    Download

    [SPEAKER INTERVIEW] - Oliver Rausch, VP Research & Development, Storm Therapeutics

    Download

    [SPEAKER INTERVIEW] - Dr. James Hamilton, Vice President, Head of Clinical Development, Arrowhead Pharmaceuticals

    Download

    [SPEAKER INTERVIEW] - Dr. Noreen Roth Henig, Chief Medical Officer, ProQR Therapeutics

    Download

    Sponsors and Exhibitors


    ChemGenes

    Sponsors and Exhibitors
    http://www.chemgenes.com

    ChemGenes, an ISO 9001 certified company established in 1981, is the industry leader in manufacturing oligonucleotide synthesis reagents and has consistently provided the highest quality phosphoramidites and solid supports in the market. Our facility, just outside of Boston/Cambridge Massachusetts USA, is setup for bulk manufacturing of therapeutic grade phosphoramidite and solid support DNA/RNA synthesis products for GMP grade oligonucleotide manufacturing. Additionally, ChemGenes carries the widest variety of modified phosphoramidites and supports currently used in oligonucleotide synthesis including Microarray Technology, Oligonucleotide Therapeutics, Oligonucleotide Based Probes and other areas of Nucleic Acid research. ChemGenes remains devoted to providing you with invaluable customer service and comprehensive technical support.


    Phion Therapeutics Ltd

    Sponsors and Exhibitors
    http://www.phiontx.co.uk

    Phion Therapeutics Ltd has developed a peptide nanoparticle for drug delivery that can deliver nucleic acids and other anionic compounds into tumors anywhere in the body at over a 30-fold the concentration relative to normal or healthy cells.

    Media Partners


    Farmavita

    Supporters
    https://farmavitar.com

    FarmavitaR+ is the professional network of experts and service providers. Network is gathering local consultants from 90 countries in Europe, Asia, North America, Latin America, Australia and Africa. Management of international, multi-centre projects is our core competence. FarmavitaR+ is providing solutions related to pharmaceutical, medical device, food supplement and cosmetic products. Scope of services is related to solutions for product development, quality assurance, clinical trials, product registration, portfolio analysis, lifecycle management, vigilance/risk management, pricing/reimbursing, market access and promotional compliance. FarmavitaR+ is brand name of Farmavita Regulanet Ltd. Visit https://farmavitar.com for more information. Outsource anything you can think of!


    Pharma Technology Focus

    Supporters
    http://www.nridigital.com/

    Pharma Technology Focus Magazine is a dynamic bi-monthly online publication available on iPad and online. It offers in-depth coverage of the most important issues and the latest developments in the pharmaceutical industry, in an innovative digital format. Brought to you by an experienced editorial and design team, Pharma Technology Focus is the essential magazine for decision-makers wanting up-to-date pharmaceutical industry news and analysis, with articles and features covering technology, discovery and development, packaging and labelling, supply chains, manufacturing and ingredients, trials and successes and much more.


    Future Science Group

    Supporters
    http://bit.ly/2A5IXar

    [Therapeutic Delivery Journal] Therapeutic Delivery offers both academics and industry professionals broad and comprehensive coverage of all aspects of the evolving drug delivery field. The journal features cutting-edge research and reviews, opinion articles on the hottest topics and a monthly industry update, written by key players in the therapeutic delivery community.


    Pharma Marketing

    Supporters
    http://magazine.pharmamkt.net/



    International Pharmaceutical Industry

    Supporters
    http://www.ipimediaworld.com

    IPI gives you an insight into all areas of Biopharm, Medical, Pharmaceutical and Healthcare. IPI provides a proven supportive means of communication to the Pharmaceutical, Bio Pharmaceutical, Nutraceutical and Medical Devices industry, incorporating the latest in research and technology innovations, regulatory guidelines, marketing and communication strategies.


    Drug Target Review

    Supporters
    http://www.drugtargetreview.com

    Drug Target Review’s quarterly magazine, website and annual events program provides high quality content with peer-written articles that are submitted exclusively by the world’s most respected scientists in their field. This attracts a committed base of readers, users and delegates made up of senior decision-makers from the life science and drug discovery industries at the top pharmaceutical companies, as well as academics and scientists from the top research institutes across the globe.


    Medical Device Network

    Supporters
    http://www.medicaldevice-network.com/

    Medicaldevice-network.com is your one stop for information on the medical device industry, covering everything along the supply chain from biomaterials and materials solutions to electronics, packaging, motors and motion control, outsourcing and more. Through our international team of journalists, we cover diagnosis, prevention, monitoring, standards, treatment and technology – all you need as a professional in the medical industry to stay abreast of the latest developments in your field.


    PharmaVOICE

    Supporters
    http://www.pharmavoice.com

    PharmaVOICE magazine, and its supporting VIEW publications, provide commentary about the challenges and trends impacting the life-sciences industry, covering a range of issues from molecule through market. PharmaVOICE's more than 41,000 U.S.-based subscribers are also kept abreast of the latest trends through additional media resources, including WebSeminars, Podcasts, Videocasts, and White Papers.


    Gate2Biotech

    Supporters
    http://www.gate2biotech.com

    Gate2Biotech is a portal that unites biotechnological community in Central Europe. It covers all the news in the field of biotechnology. Thanks to the the portal the companies engaged in the field can easily search for research institutions and other partners to solve technical problems they are facing and here they can also present their services offer to potential partners from the Czech Republic and abroad. Gate2Biotech portal serves as a bridge connecting scientific and commercial sector. It incorporates offices and support organizations dedicated to promoting transfer of innovative technologies into a unified communication platform of Czech and international biotechnologies. As a mediator of information it draws attention to biotechnologies and support of their application and transfer into practice. It also functions as a tool for encouraging non-professionals (especially scientists and students) towards innovative business or applied research.


    Biosave

    Supporters
    http://www.Biosave.com

    Biosave.com brings together the best Life Science promotions, product releases, featured products, publications, videos and events from 100’s of leading Life Science suppliers. Updated 24 hours a day, Biosave is constantly uploading special promotions and exciting product news that you won’t find anywhere else. Our goal is to provide our users with the most exclusive product information to help reach that all important purchasing decision.


    Absave

    Supporters
    http://www.absave.com

    Absave.com is the leading savings website for Antibodies and Immunological Products. Search our extensive database of Antibodies, Kits, Proteins & Peptides, Reagents, etc. to find the best savings!


    Journal for Clinical Studies – Your Resource for Multisite Studies & Emerging Markets

    Supporters
    http://www.JforCS.com

    Published bi-monthly.JCS is a unique journal, dedicated to providing information to the global pharmaceutical, biotechnology, medical devices and contract research organisations. JCS details practical and theoretical operational procedures, challenges, validatory and regulatory guidelines when conducting trials on a multisite basis and particularly within the emerging markets, naïve patient population, and remote access areas. JCS provides country by country objectives and uniquely brings you experiences in therapeutic areas of Liver diseases, kidney diseases, insect borne diseases, malnutrition and under nutrition. JCS is led by a strong editorial advisory board sourced out for their experiences; you will get the most practical insight for your global studies. JCS invites you to join us, write for us, feature your experiences with us, advertise your capabilities with us, and ask our advisory board for suggestions and guidelines. Let us make health care available to all.


    Labiotech.eu

    Supporters
    https://goo.gl/DRE2Gp

    Labiotech.eu is the leading digital media covering the European Biotech industry. Over 100,000 monthly visitors use it to keep an eye on the business and innovations in biotechnology. Hope you'll enjoy reading our stories!


    Drug Discovery Today

    Supporters
    http://www.drugdiscoverytoday.com/

    Drug Discovery Today covers the whole of the preclinical drug discovery process. The reviews are cutting edge, written by experts in their respective fields and cover all aspects of drug discovery from genomic and proteomic approaches, computational drug design, medicinal chemistry and the translation of these sciences to therapies.


    Technology Networks

    Supporters
    http://go.technologynetworks.com/subscribe-to-newsletters

    Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com


    World Pharma News

    Supporters
    http://www.worldpharmanews.com/



    Labsave

    Supporters
    http://www.labsave.com

    Labsave is the leading savings website for Laboratory Equipment and Lab Supplies. We work closely with the top suppliers in the world to bring you the best products at the most competitive prices. We are constantly striving to secure the biggest and most exclusive offers that you won’t find anywhere else! http://www.labsave.com/


    pharmaphorum

    Supporters
    http://www.pharmaphorum.com

    pharmaphorum drives innovation within the pharmaceutical industry, by bringing healthcare together through a suite of media services that help produce and disseminate thought leadership, combined with an online platform for communicating messages to a global audience.Visit www.pharmaphorum.com


    Biocompare

    Supporters
    http://www.biocompare.com

    Biocompare.com is the leading resource for up-to-date product information, product reviews, and new technologies for life scientists. Biocompare combines an in-depth knowledge of life science products and new technologies with the power of the Internet to offer scientists the most dynamic, relevant, and innovative media-based marketplace for life science information.

    Holiday Inn Kensington Forum

    97 Cromwell Road
    London SW7 4DN
    United Kingdom

    Holiday Inn Kensington Forum

    Holiday Inn Kensington Forum is perfectly situated in one of London’s most luxurious and beautiful areas within South Kensington. 

    The hotel is just 2 minutes walk from Gloucester Road tube station for convenient travel to Hyde Park, London Eye, Tower Bridge plus more of London’s top attractions. There are also easy and direct links to some major transport hubs including Victoria, Kings Cross St Pancras, Paddington and Heathrow. 

    This distinctive hotel in south London has so much to offer to make all guests really feel at home. The latest Holiday Inn relaunch is not just about the new look and feel for the hotel but to offer guests more benefits during their stay including a pillow menu for extra comfort during their sleep and a curved shower rail for more spacious feel. 

    In addition to our 906 rooms, all business guests can take advantage of our meeting and conference facilities including High Speed Internet Access and unlimited Starbucks coffee at The Academy. Our hotel’s professional event planners are on board to help take the hard work and stress away from planning your next event. 

    So whether you in London on business or pleasure, make the Holiday Inn London Kensington Forum your first choice of hotel and book your accommodation for our lowest internet rate guarantee. 

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download

    Title


    Description

    Download

    Title


    Description


    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    Group Booking

    Please complete the below form and a member of SAE Media Group’s booking team will be in contact within 24 hours

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SAE Media Group

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smgconferences.com Email: events@saemediagroup.com
    Registered in England - SMi Group Ltd trading as SAE Media Group




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data.privacy@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out

    Fill in your details to download the brochure

    By submitting this form you agree to our privacy policy and consent to receiving communications, you may opt out at any time.